PCART7 is under clinical development by MediSix Therapeutics and currently in Phase I for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia). According to GlobalData, Phase I drugs for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PCART7’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PCART7 is under development for the treatment of relapsed or refractory T-lineage acute lymphoblastic leukemia (T-ALL), acute myelocytic leukemia and T-cell acute lymphocytic leukemia(T-LL). The therapy comprises of T cells, which are genetically manipulated to express chimeric antigen receptor (CAR). It is administered through parenteral route.
MediSix Therapeutics overview
MediSix Therapeutics Pte. Ltd., immune engineering company that developing novel cellular therapies to address T cell malignancies. The company is headquartered in Singapore.
For a complete picture of PCART7’s drug-specific PTSR and LoA scores, buy the report here.